{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:25:56Z","timestamp":1790400356172,"version":"4.1.0"},"reference-count":97,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","funder":[{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"publisher","award":["81570611\/H0503"],"award-info":[{"award-number":["81570611\/H0503"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"publisher","award":["81770675\/H0503"],"award-info":[{"award-number":["81770675\/H0503"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:p>The mammalian target of rapamycin (mTOR), a serine\/threonine protein kinase, is crucial in regulating cell growth, metabolism, proliferation, and survival. Under physiologic conditions, mTOR signaling maintains podocyte and tubular cell homeostasis. In AKI, activation of mTOR signaling in tubular cells and interstitial fibroblasts promotes renal regeneration and repair. However, constitutive activation of mTOR signaling in kidneys results in the initiation and progression of glomerular hypertrophy, interstitial fibrosis, polycystic kidney disease, and renal cell carcinoma. Here, we summarize the recent studies about mTOR signaling in renal physiology and injury, and discuss the possibility of its use as a therapeutic target for kidney diseases.<\/jats:p>","DOI":"10.34067\/kid.0003782020","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T18:05:17Z","timestamp":1599156317000},"page":"1319-1327","source":"Crossref","is-referenced-by-count":66,"title":["mTOR Signaling in Kidney Diseases"],"prefix":"10.34067","volume":"1","author":[{"given":"Yuan","family":"Gui","sequence":"first","affiliation":[{"name":"Department of Nephrology, University of Connecticut Health Center, Farmington, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsun","family":"Dai","sequence":"additional","affiliation":[{"name":"Center for Kidney Disease, 2nd Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"key":"B1-20230821","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"V\u00e9zina","year":"1975","journal-title":"J Antibiot (Tokyo)"},{"key":"B2-20230821","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.7164\/antibiotics.37.1231","article-title":"Activity of rapamycin (AY-22,989) against transplanted tumors","volume":"37","author":"Eng","year":"1984","journal-title":"J Antibiot (Tokyo)"},{"key":"B3-20230821","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1091\/mbc.5.1.105","article-title":"TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast","volume":"5","author":"Helliwell","year":"1994","journal-title":"Mol Biol Cell"},{"key":"B4-20230821","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"169","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"B5-20230821","doi-asserted-by":"crossref","first-page":"E2817","DOI":"10.1073\/pnas.1402352111","article-title":"mTORC1 maintains renal tubular homeostasis and is essential in response to ischemic stress","volume":"111","author":"Grahammer","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B6-20230821","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ki.2013.559","article-title":"Rictor\/mTORC2 protects against cisplatin-induced tubular cell death and acute kidney injury","volume":"86","author":"Li","year":"2014","journal-title":"Kidney Int"},{"key":"B7-20230821","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/ki.2015.119","article-title":"Rictor\/mTORC2 signaling mediates TGF\u03b21-induced fibroblast activation and kidney fibrosis","volume":"88","author":"Li","year":"2015","journal-title":"Kidney Int"},{"key":"B8-20230821","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1681\/ASN.2012050476","article-title":"Rheb\/mTORC1 signaling promotes kidney fibroblast activation and fibrosis","volume":"24","author":"Jiang","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B9-20230821","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1172\/JCI44774","article-title":"Role of mTOR in podocyte function and diabetic nephropathy in humans and mice","volume":"121","author":"G\u00f6del","year":"2011","journal-title":"J Clin Invest"},{"key":"B10-20230821","doi-asserted-by":"crossref","first-page":"F1023","DOI":"10.1152\/ajprenal.00018.2014","article-title":"Mammalian target of rapamycin complex 1 activation in podocytes promotes cellular crescent formation","volume":"307","author":"Mao","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"B11-20230821","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B12-20230821","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/MCB.01259-08","article-title":"Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1","volume":"29","author":"Distefano","year":"2009","journal-title":"Mol Cell Biol"},{"key":"B13-20230821","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nrc2501","article-title":"Hypoxia signalling through mTOR and the unfolded protein response in cancer","volume":"8","author":"Wouters","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B14-20230821","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0041-1345(00)02141-2","article-title":"Rapamycin reduces expression of fibrosis-associated genes in an experimental model of renal ischaemia reperfusion injury","volume":"33","author":"Jain","year":"2001","journal-title":"Transplant Proc"},{"key":"B15-20230821","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/ndt\/gfq496","article-title":"The PI3K\/Akt\/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin","volume":"26","author":"Stylianou","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B16-20230821","doi-asserted-by":"crossref","first-page":"e54918","DOI":"10.1371\/journal.pone.0054918","article-title":"A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"B17-20230821","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0092-8674(02)00833-4","article-title":"Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action","volume":"110","author":"Hara","year":"2002","journal-title":"Cell"},{"key":"B18-20230821","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2009.03.046","article-title":"DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival","volume":"137","author":"Peterson","year":"2009","journal-title":"Cell"},{"key":"B19-20230821","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"B20-20230821","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.cub.2006.08.001","article-title":"mSin1 is necessary for Akt\/PKB phosphorylation, and its isoforms define three distinct mTORC2s","volume":"16","author":"Frias","year":"2006","journal-title":"Curr Biol"},{"key":"B21-20230821","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","article-title":"Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb","volume":"13","author":"Tee","year":"2003","journal-title":"Curr Biol"},{"key":"B22-20230821","doi-asserted-by":"crossref","first-page":"13375","DOI":"10.1074\/jbc.273.22.13375","article-title":"The tumor suppressor, PTEN\/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate","volume":"273","author":"Maehama","year":"1998","journal-title":"J Biol Chem"},{"key":"B23-20230821","doi-asserted-by":"crossref","first-page":"13489","DOI":"10.1073\/pnas.0405659101","article-title":"Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase","volume":"101","author":"Roux","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B24-20230821","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Inoki","year":"2003","journal-title":"Cell"},{"key":"B25-20230821","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1101\/gad.1256804","article-title":"Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1\/TSC2 tumor suppressor complex","volume":"18","author":"Brugarolas","year":"2004","journal-title":"Genes Dev"},{"key":"B26-20230821","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1101\/gad.1617608","article-title":"Hypoxia regulates TSC1\/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling","volume":"22","author":"DeYoung","year":"2008","journal-title":"Genes Dev"},{"key":"B27-20230821","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1126\/science.1157535","article-title":"The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1","volume":"320","author":"Sancak","year":"2008","journal-title":"Science"},{"key":"B28-20230821","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cell.2010.02.024","article-title":"Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids","volume":"141","author":"Sancak","year":"2010","journal-title":"Cell"},{"key":"B29-20230821","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.cell.2006.06.055","article-title":"TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth","volume":"126","author":"Inoki","year":"2006","journal-title":"Cell"},{"key":"B30-20230821","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cell.2007.05.058","article-title":"IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"key":"B31-20230821","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1158\/0008-5472.CAN-06-4149","article-title":"The regulation of AMPK beta1, TSC2, and PTEN expression by p53: Stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways","volume":"67","author":"Feng","year":"2007","journal-title":"Cancer Res"},{"key":"B32-20230821","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1158\/2159-8290.CD-15-1125","article-title":"The SIN1-PH domain connects mTORC2 to PI3K","volume":"5","author":"Yuan","year":"2015","journal-title":"Cancer Discov"},{"key":"B33-20230821","doi-asserted-by":"crossref","first-page":"10998","DOI":"10.1074\/jbc.M110.195016","article-title":"Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3,4,5-trisphosphate","volume":"286","author":"Gan","year":"2011","journal-title":"J Biol Chem"},{"key":"B34-20230821","doi-asserted-by":"crossref","first-page":"eaav3249","DOI":"10.1126\/scisignal.aav3249","article-title":"AMPK directly activates mTORC2 to promote cell survival during acute energetic stress","volume":"12","author":"Kazyken","year":"2019","journal-title":"Sci Signal"},{"key":"B35-20230821","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1038\/s41467-018-07277-9","article-title":"Crosstalks between mTORC1 and mTORC2 variagate cytokine signaling to control NK maturation and effector function","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"B36-20230821","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/ncb2860","article-title":"Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis","volume":"15","author":"Liu","year":"2013","journal-title":"Nat Cell Biol"},{"key":"B37-20230821","first-page":"e28174","article-title":"Signaling crosstalk between the mTOR complexes","volume":"2","author":"Xie","year":"2014","journal-title":"Translation (Austin)"},{"key":"B38-20230821","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1038\/s41418-019-0336-3","article-title":"Fibroblast mTOR\/PPAR\u03b3\/HGF axis protects against tubular cell death and acute kidney injury","volume":"26","author":"Gui","year":"2019","journal-title":"Cell Death Differ"},{"key":"B39-20230821","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41419-020-2539-4","article-title":"Rheb1 protects against cisplatin-induced tubular cell death and acute kidney injury via maintaining mitochondrial homeostasis","volume":"11","author":"Lu","year":"2020","journal-title":"Cell Death Dis"},{"key":"B40-20230821","doi-asserted-by":"crossref","first-page":"F693","DOI":"10.1152\/ajprenal.2001.281.4.F693","article-title":"Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells","volume":"281","author":"Lieberthal","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"B41-20230821","doi-asserted-by":"crossref","first-page":"e2695","DOI":"10.1038\/cddis.2017.86","article-title":"The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury","volume":"8","author":"Zhang","year":"2017","journal-title":"Cell Death Dis"},{"key":"B42-20230821","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.4049\/jimmunol.1601251","article-title":"mTOR signaling regulates protective activity of transferred CD4+Foxp3+ T cells in repair of acute kidney injury","volume":"197","author":"Chen","year":"2016","journal-title":"J Immunol"},{"key":"B43-20230821","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/01.ASN.0000057542.86377.5A","article-title":"Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use","volume":"14","author":"Smith","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"B44-20230821","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2249.2011.04487.x","article-title":"Preconditioning donor with a combination of tacrolimus and rapamacyn to decrease ischaemia-reperfusion injury in a rat syngenic kidney transplantation model","volume":"167","author":"Cicora","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"B45-20230821","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000348496","article-title":"Effects of everolimus on oxidative stress in kidney model of ischemia\/reperfusion injury","volume":"37","author":"Kezic","year":"2013","journal-title":"Am J Nephrol"},{"key":"B46-20230821","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1681\/ASN.2004030180","article-title":"Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy","volume":"16","author":"Bonegio","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B47-20230821","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1038\/sj.ki.5000161","article-title":"Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis","volume":"69","author":"Wu","year":"2006","journal-title":"Kidney Int"},{"key":"B48-20230821","doi-asserted-by":"crossref","first-page":"e42316","DOI":"10.1371\/journal.pone.0042316","article-title":"TGF\u03b2-stimulated microRNA-21 utilizes PTEN to orchestrate AKT\/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion","volume":"7","author":"Dey","year":"2012","journal-title":"PLoS One"},{"key":"B49-20230821","doi-asserted-by":"crossref","first-page":"F1214","DOI":"10.1152\/ajprenal.00710.2010","article-title":"Albumin-induced epithelial-mesenchymal transition and ER stress are regulated through a common ROS-c-Src kinase-mTOR pathway: Effect of imatinib mesylate","volume":"300","author":"Lee","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"B50-20230821","doi-asserted-by":"crossref","first-page":"16364","DOI":"10.1074\/jbc.RA118.004073","article-title":"Yap\/Taz mediates mTORC2-stimulated fibroblast activation and kidney fibrosis","volume":"293","author":"Gui","year":"2018","journal-title":"J Biol Chem"},{"key":"B51-20230821","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/path.4921","article-title":"Rictor\/mammalian target of rapamycin complex 2 promotes macrophage activation and kidney fibrosis","volume":"242","author":"Ren","year":"2017","journal-title":"J Pathol"},{"key":"B52-20230821","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1126\/science.1205407","article-title":"Spatial coupling of mTOR and autophagy augments secretory phenotypes","volume":"332","author":"Narita","year":"2011","journal-title":"Science"},{"key":"B53-20230821","doi-asserted-by":"crossref","first-page":"eaav4754","DOI":"10.1126\/scitranslmed.aav4754","article-title":"Cyclin G1 and TASCC regulate kidney epithelial cell G2-M arrest and fibrotic maladaptive repair","volume":"11","author":"Canaud","year":"2019","journal-title":"Sci Transl Med"},{"key":"B54-20230821","doi-asserted-by":"crossref","first-page":"F418","DOI":"10.1152\/ajprenal.90319.2008","article-title":"mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes","volume":"296","author":"Vollenbr\u00f6ker","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"B55-20230821","doi-asserted-by":"crossref","first-page":"e55980","DOI":"10.1371\/journal.pone.0055980","article-title":"Protective effects of the mTOR inhibitor everolimus on cytoskeletal injury in human podocytes are mediated by RhoA signaling","volume":"8","author":"Jeruschke","year":"2013","journal-title":"PLoS One"},{"key":"B56-20230821","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1681\/ASN.2011070690","article-title":"Inhibition of MTOR disrupts autophagic flux in podocytes","volume":"23","author":"Cin\u00e0","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B57-20230821","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1172\/JCI39492","article-title":"Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice","volume":"120","author":"Hartleben","year":"2010","journal-title":"J Clin Invest"},{"key":"B58-20230821","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/path.5077","article-title":"Advanced glycation end-products suppress autophagic flux in podocytes by activating mammalian target of rapamycin and inhibiting nuclear translocation of transcription factor EB","volume":"245","author":"Zhao","year":"2018","journal-title":"J Pathol"},{"key":"B59-20230821","doi-asserted-by":"crossref","first-page":"e3006","DOI":"10.1038\/cddis.2017.414","article-title":"Apelin involved in progression of diabetic nephropathy by inhibiting autophagy in podocytes","volume":"8","author":"Liu","year":"2017","journal-title":"Cell Death Dis"},{"key":"B60-20230821","doi-asserted-by":"crossref","first-page":"F74","DOI":"10.1152\/ajprenal.00114.2017","article-title":"Autophagy is activated to protect against podocyte injury in adriamycin-induced nephropathy","volume":"313","author":"Yi","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"B61-20230821","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2018-213028","article-title":"Increased autophagy is cytoprotective against podocyte injury induced by antibody and interferon-\u03b1 in lupus nephritis","volume":"77","author":"Qi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B62-20230821","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1681\/ASN.2016050519","article-title":"Targeting mTOR signaling can prevent the progression of FSGS","volume":"28","author":"Zschiedrich","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B63-20230821","first-page":"321","article-title":"Use of sirolimus in patients with primary steroid-resistant nephrotic syndrome","volume":"32","author":"Liern","year":"2012","journal-title":"Nefrologia"},{"key":"B64-20230821","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.ajkd.2008.12.024","article-title":"Rapamycin for focal segmental glomerulosclerosis: A report of 3 cases","volume":"54","author":"Tsagalis","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"B65-20230821","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2215\/CJN.00120605","article-title":"A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis","volume":"1","author":"Tumlin","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"B66-20230821","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1681\/ASN.2016111196","article-title":"Mesangial cell mammalian target of rapamycin complex 1 activation results in mesangial expansion","volume":"28","author":"Nagai","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B67-20230821","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1177\/1535370214555666","article-title":"Rapamycin ameliorates IgA nephropathy via cell cycle-dependent mechanisms","volume":"240","author":"Tian","year":"2015","journal-title":"Exp Biol Med (Maywood)"},{"key":"B68-20230821","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1440-1797.2012.01646.x","article-title":"Proliferation signal inhibitors in the treatment of lupus nephritis: Preliminary experience","volume":"17","author":"Yap","year":"2012","journal-title":"Nephrology (Carlton)"},{"key":"B69-20230821","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.18632\/aging.100925","article-title":"Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL\/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway","volume":"8","author":"Gu","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"B70-20230821","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1093\/ndt\/gfr072","article-title":"Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy","volume":"26","author":"Cruzado","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B71-20230821","first-page":"189","article-title":"Tubular epithelial cell and podocyte apoptosis with de novo sirolimus based immunosuppression in renal allograft recipients with DGF","volume":"25","author":"Munivenkatappa","year":"2010","journal-title":"Histol Histopathol"},{"key":"B72-20230821","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2215\/CJN.03751106","article-title":"High sirolimus levels may induce focal segmental glomerulosclerosis de novo","volume":"2","author":"Letavernier","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"B73-20230821","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B74-20230821","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1038\/s41467-020-16978-z","article-title":"mTOR and S6K1 drive polycystic kidney by the control of Afadin-dependent oriented cell division","volume":"11","author":"Bonucci","year":"2020","journal-title":"Nat Commun"},{"key":"B75-20230821","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ndt\/gfi181","article-title":"Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)","volume":"21","author":"Wahl","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"B76-20230821","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1681\/ASN.2004080660","article-title":"Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease","volume":"16","author":"Tao","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B77-20230821","doi-asserted-by":"crossref","first-page":"F187","DOI":"10.1152\/ajprenal.00051.2019","article-title":"A study of sirolimus and mTOR kinase inhibitor in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease","volume":"317","author":"Holditch","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"B78-20230821","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/jcmm.13091","article-title":"Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1\/cyclin axis","volume":"21","author":"Li","year":"2017","journal-title":"J Cell Mol Med"},{"key":"B79-20230821","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1093\/hmg\/ddu208","article-title":"An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2","volume":"23","author":"Ravichandran","year":"2014","journal-title":"Hum Mol Genet"},{"key":"B80-20230821","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10157-016-1289-1","article-title":"Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells","volume":"21","author":"de Stephanis","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"B81-20230821","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1038\/s41598-018-22938-x","article-title":"Dual mTOR\/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease","volume":"8","author":"Liu","year":"2018","journal-title":"Sci Rep"},{"key":"B82-20230821","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"B83-20230821","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2215\/CJN.02650313","article-title":"Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: An open-label randomized controlled pilot study","volume":"9","author":"Braun","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B84-20230821","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"B85-20230821","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.2011040340","article-title":"Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease","volume":"23","author":"Novalic","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B86-20230821","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/ki.2009.296","article-title":"The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy","volume":"76","author":"Clark","year":"2009","journal-title":"Kidney Int"},{"key":"B87-20230821","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ctrv.2012.12.015","article-title":"Differentiating mTOR inhibitors in renal cell carcinoma","volume":"39","author":"Pal","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"B88-20230821","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1476-4598-10-90","article-title":"Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K\/mTOR inhibitor, in combination with sorafenib","volume":"10","author":"Roulin","year":"2011","journal-title":"Mol Cancer"},{"key":"B89-20230821","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cellsig.2011.08.013","article-title":"Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K\/mTOR\/p70S6K pathway by interacting of VEGFR-2","volume":"24","author":"Rho","year":"2012","journal-title":"Cell Signal"},{"key":"B90-20230821","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.canlet.2014.11.012","article-title":"Pre-clinical evaluation of AZD-2014, a novel mTORC1\/2 dual inhibitor, against renal cell carcinoma","volume":"357","author":"Zheng","year":"2015","journal-title":"Cancer Lett"},{"key":"B91-20230821","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.eururo.2015.08.035","article-title":"A randomised phase 2 study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer","volume":"69","author":"Powles","year":"2016","journal-title":"Eur Urol"},{"key":"B92-20230821","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/01.tp.0000225772.22757.5e","article-title":"Rapamycin delays but does not prevent recovery from acute renal failure: Role of acquired tubular resistance","volume":"82","author":"Lieberthal","year":"2006","journal-title":"Transplantation"},{"key":"B93-20230821","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1034\/j.1600-6143.2003.00078.x","article-title":"Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation","volume":"3","author":"McTaggart","year":"2003","journal-title":"Am J Transplant"},{"key":"B94-20230821","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/ndt\/gfn574","article-title":"Sirolimus interacts with pathways essential for podocyte integrity","volume":"24","author":"Letavernier","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B95-20230821","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.bbrc.2005.12.012","article-title":"Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice","volume":"340","author":"Sakaguchi","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"B96-20230821","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/j.1600-6143.2005.01013.x","article-title":"Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing","volume":"5","author":"Senior","year":"2005","journal-title":"Am J Transplant"},{"key":"B97-20230821","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.tips.2014.11.004","article-title":"Current treatment strategies for inhibiting mTOR in cancer","volume":"36","author":"Chiarini","year":"2015","journal-title":"Trends Pharmacol Sci"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0003782020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:57:15Z","timestamp":1786478235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0003782020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":97,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0003782020","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}